Back to list

Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancer

geo / GSE318308

Dataset

Provider: GEO
Type: bulk
Organism: Homo sapiens (tax 9606)
Format / file: archive_table — GSE318308_RAW.tar (183 MB)
Matrix: 75 samples
Source page: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318308
Download URL: https://ftp.ncbi.nlm.nih.gov/geo/series/GSE318nnn/GSE318308/suppl/GSE318308_RAW.tar

DOIs

None

PubMed IDs

None

Accessions

Not in ASAP yet.